As Psychedelic Care Gets Leaner, the Integration Work Moves Home. Our Data Says Home Is a Coin Flip
The short answer: A new paper in the Canadian Journal of Psychiatry says psychedelic treatment is getting leaner. The psychological work that integration sessions used to do now falls to patients’ families and friends. Our own survey data suggests those households are close to a coin flip.
Follow up structure and support staffing are decisions a clinic controls without waiting for a regulator. HealingMaps’ GPO, the first built for the ketamine industry, gets member clinics 40 percent or more off medical supplies, 15 to 20 percent off malpractice and liability premiums, discounted LegitScript certification, and 20 to 30 percent off HIPAA compliant payment processing. Joining is free with no obligation. See what your clinic qualifies for →
| What the paper says | Why it matters to your clinic |
|---|---|
| Published August 25, 2026 in the Canadian Journal of Psychiatry | A Perspective piece, not a trial. It reports no new outcome data |
| Cutting clinical contact displaces integration onto patients’ social environments | At-home and low-touch protocols are the leanest models in ketamine care |
| Those environments go unmeasured in research protocols | An unmeasured variable may be moving your outcomes either way |
| HealingMaps survey: patients split evenly on supporting versus stopping a family member | The household is not a dependable substitute for clinical contact |
| Authors urge screening for support, not screening people out | A weak support network should trigger more care, not exclusion |
What the Paper Actually Argues
The lead author is Edward Jacobs of the Center for Psychedelic and Consciousness Research at Johns Hopkins. He is joined by Ian Roullier of the Psychedelic Participant Advocacy Network, Rosalind Watts of ACER Integration, and Hattie Wells of Hammersmith Medicines Research. Their paper published on August 25, 2026, with a free copy on Zenodo.
Their case is that treatment is shifting from psychedelic-assisted therapy toward psychedelics with psychological support. In that second model the clinician ensures safety during dosing rather than actively guiding change. The processing work that integration sessions handled does not disappear when those sessions are cut. It moves to whoever is around the patient, or it goes unmet.
This is a Perspective, not a study. The authors say plainly that direct evidence for integration’s contribution to outcomes remains limited. They are arguing that a question deserves measurement, not announcing a finding.
Regulators have already asked a version of it. The FDA’s rejection letter on the Lykos MDMA application recommended that future studies characterize what the psychotherapy component contributes.
We Asked Patients What They Would Actually Do
One HealingMaps community survey put close to the paper’s exact question to patients. It asked what they would do if a friend or family member were injecting ketamine at home. We coded all 30 open-ended answers.
Thirty responses is a small, self-selected sample, and it says nothing about outcomes. It does put numbers on the paper’s central claim that social environments vary enormously in what they can absorb.
Patients Want Access, Not Unsupervised Dosing
In a related survey, 64.8 percent called at-home ketamine injectables a bad idea (n=54). Yet 58.1 percent said telehealth increases access to psychedelic therapies, against 25.7 percent who said in-person supervision is necessary (n=74). The objection is to unsupervised administration, not to convenience.
The pressure driving leaner models is real for these same patients. Asked about barriers, 44.9 percent named lack of local access and 36.7 percent named cost. Clinics are being pushed toward cheaper, lighter delivery by patients who also say they do not want to dose alone.
The Problem With Generalizing From Trials
The authors raise a sharper concern. Psychedelic trial samples overrepresent well-educated and financially secure participants and underrepresent people of color and other marginalized groups. Those are the people most likely to have the social resources that absorb integration work.
If social environment does moderate outcomes, then both the effect sizes and the adverse event rates reported in existing trials may not carry over to a broader population. That echoes what SAMHSA told states this same week, flagging that research has largely excluded the populations public mental health systems serve.
What Clinics Can Do Now
The paper proposes three responses. Give families structured psychoeducation before treatment so they read emotional shifts as part of the process rather than as new symptoms. Build peer support designed for clinical populations, since groups aimed at recreational or retreat users tend to fit poorly. Add validated social-environment measures to research protocols, using instruments that already exist.
One recommendation deserves attention from anyone writing intake criteria. The authors argue that a weak or hostile support network should serve as an indicator for enhanced support rather than as an exclusionary screen. That is the opposite of how screening usually gets applied.
One Disclosure Worth Weighing
Two of the four authors have a commercial stake in what they recommend. Roullier has piloted a peer support model through his advocacy network, and Watts founded and directs a paid long-term integration programme. Both facts appear in the paper’s own declaration.
That does not sink the argument, which rests on cited work across oncology, bereavement care, and mental health treatment generally. It does mean readers should weigh a call to invest in integration infrastructure against the fact that some of its authors build integration infrastructure.
READ NEXT: Every Psychedelic Company Is Racing to Get the Patient Out of the Chair Faster
